End-organ damage in hypertensive transgenic Ren-2 rats: influence of early and late endothelin receptor blockade
- PMID: 20131938
- DOI: 10.33549/physiolres.931640
End-organ damage in hypertensive transgenic Ren-2 rats: influence of early and late endothelin receptor blockade
Abstract
The rat strain transgenic for the murine Ren-2 renin gene (TGR) is defined as a monogenic model of angiotensin II-dependent hypertension with endogenous activation of the renin-angiotensin system. Homozygous males TGR develop malignant hypertension with a strong salt-sensitive component. These animals show severe hypertension, proteinuria and high mortality. Morphological changes of renal parenchyma correspond to chronic ischemic glomerular changes. Heterozygous TGR develop only mild hypertension and thus provide a more suitable model of hypertension regarding to clinical studies. Within the renal parenchyma, secondary focal segmental glomerulosclerosis (FSGS) predominates. High-salt diet in heterozygous animals induces transition from benign to malignant phase of hypertension. In this case, ischemic glomerular changes are superimposed on preexisting secondary FSGS. In the regression model of hypertension (late-onset treatment) the effect of salt intake is attenuated. In homozygous TGR, early selective ET(A) receptor blockade decreased blood pressure and ameliorated end-organ damage. Late selective ET(A) receptor blockade reduced podocyte injury despite final severe hypertension. Survival rate was markedly improved in both regimens with ET(A) selective blockade, while there was only partial improvement with early non-selective blockade. Both bosentan and atrasentan decreased ET-1 levels in both regimens. In heterozygous TGR, early and late ET(A) treatment substantially while ET(A)/ET(B) treatment partially improved survival rate. Significant effect on BP was found with early and late ET(A) blockade, while ET(A)/ET(B) blockade had no effect. Bosentan and atrasentan similarly decreased ET-1 levels on both regimens. In conclusion, selective ET(A) receptor blockade is superior to nonselective ET(A)/ET(B) receptor blockade in attenuating hypertension and end-organ damage. Its effect is more pronounced when applied early in the life.
Similar articles
-
Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats.Vascul Pharmacol. 2006 Sep;45(3):163-70. doi: 10.1016/j.vph.2006.05.003. Epub 2006 May 16. Vascul Pharmacol. 2006. PMID: 16807127
-
Late-onset endothelin receptor blockade in hypertensive heterozygous REN-2 transgenic rats.Vascul Pharmacol. 2008 Apr-Jun;48(4-6):165-73. doi: 10.1016/j.vph.2008.01.009. Epub 2008 Feb 12. Vascul Pharmacol. 2008. PMID: 18372220
-
Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension.Hypertension. 2006 Nov;48(5):965-71. doi: 10.1161/01.HYP.0000245117.57524.d6. Epub 2006 Oct 2. Hypertension. 2006. PMID: 17015777
-
Renoprotective effects of ET(A) receptor antagonists therapy in experimental non-diabetic chronic kidney disease: Is there still hope for the future?Physiol Res. 2018 Jun 27;67(Suppl 1):S55-S67. doi: 10.33549/physiolres.933898. Physiol Res. 2018. PMID: 29947528 Review.
-
Endothelin and endothelin antagonists in hypertension.J Hypertens. 1998 Dec;16(12 Pt 2):1891-5. doi: 10.1097/00004872-199816121-00007. J Hypertens. 1998. PMID: 9886874 Review.
Cited by
-
Sex differences in blood pressure, free radicals and plasma cholesterol fractions in Ren-2 transgenic rats of various ages.Physiol Res. 2023 Apr 30;72(2):167-175. doi: 10.33549/physiolres.935059. Physiol Res. 2023. PMID: 37159851 Free PMC article.
-
Pathomechanisms of Prenatally Programmed Adult Diseases.Antioxidants (Basel). 2023 Jun 28;12(7):1354. doi: 10.3390/antiox12071354. Antioxidants (Basel). 2023. PMID: 37507894 Free PMC article. Review.
-
A case of secondary focal segmental glomerulosclerosis associated with malignant hypertension.CEN Case Rep. 2013 May;2(1):68-75. doi: 10.1007/s13730-012-0041-2. Epub 2012 Dec 7. CEN Case Rep. 2013. PMID: 28509227 Free PMC article.
-
Alkali supplementation as a therapeutic in chronic kidney disease: what mediates protection?Am J Physiol Renal Physiol. 2020 Dec 1;319(6):F1090-F1104. doi: 10.1152/ajprenal.00343.2020. Epub 2020 Nov 9. Am J Physiol Renal Physiol. 2020. PMID: 33166183 Free PMC article. Review.
-
Sex differences in blood pressure of aged Ren-2 transgenic rats.Physiol Res. 2020 Apr 30;69(2):245-252. doi: 10.33549/physiolres.934369. Epub 2020 Mar 23. Physiol Res. 2020. PMID: 32199017 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous